Abstract
Digital ulcers in patients with systemic sclerosis (SSc) can cause considerable disability; however, clinical trials addressing the treatment and prevention of digital ulcers in SSc are rare. A study has evaluated the potential benefit of the endothelin receptor antagonist bosentan in the treatment of SSc-related digital ulcers.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
